TY - JOUR
T1 - Alternatives to Topical Glaucoma Medication for Glaucoma Management
AU - Bedrood, Sahar
AU - Berdahl, John
AU - Sheybani, Arsham
AU - Singh, Inder Paul
N1 - Publisher Copyright:
© 2023 Bedrood et al.
PY - 2023
Y1 - 2023
N2 - Topical glaucoma medications have favorable safety and efficacy, but their use is limited by factors such as side effects, nonadherence, costs, ocular surface disease, intraocular pressure fluctuations, diminished quality of life, and the inherent difficulty of penetrating the corneal surface. Although traditionally these limitations have been accepted as an inevitable part of glaucoma treatment, a rapidly-evolving arena of minimally invasive surgical and laser interventions has initiated the beginnings of a reevaluation of the glaucoma treatment paradigm. This reevaluation encompasses an overall shift away from the reactive, topical-medication-first default and a shift toward earlier intervention with laser or surgical therapies such as selective laser trabeculoplasty, sustained-release drug delivery, and micro-invasive glaucoma surgery. Aside from favorable safety, these interventions may have clinically important attributes such as consistent IOP control, cost-effectiveness, independence from patient adherence, prevention of disease progression, and improved quality of life.
AB - Topical glaucoma medications have favorable safety and efficacy, but their use is limited by factors such as side effects, nonadherence, costs, ocular surface disease, intraocular pressure fluctuations, diminished quality of life, and the inherent difficulty of penetrating the corneal surface. Although traditionally these limitations have been accepted as an inevitable part of glaucoma treatment, a rapidly-evolving arena of minimally invasive surgical and laser interventions has initiated the beginnings of a reevaluation of the glaucoma treatment paradigm. This reevaluation encompasses an overall shift away from the reactive, topical-medication-first default and a shift toward earlier intervention with laser or surgical therapies such as selective laser trabeculoplasty, sustained-release drug delivery, and micro-invasive glaucoma surgery. Aside from favorable safety, these interventions may have clinically important attributes such as consistent IOP control, cost-effectiveness, independence from patient adherence, prevention of disease progression, and improved quality of life.
KW - MIGS
KW - intervention
KW - medication
KW - selective laser trabeculoplasty
KW - sustained release drug delivery
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85179734159&partnerID=8YFLogxK
U2 - 10.2147/OPTH.S439457
DO - 10.2147/OPTH.S439457
M3 - Article
C2 - 38111854
AN - SCOPUS:85179734159
SN - 1177-5467
VL - 17
SP - 3899
EP - 3913
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
ER -